Moreover, preclinical studies suggest that the inhibition of both TIM-3 and PD-1/PD-L1 has a synergistic effect, leading to the re-invigoration of T-cell function and enhanced anti-tumor immunity [128, 135, 136]. Here, CD274 is linked to neoplasm.